Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30


Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review.

Crozier JA, Sher T, Yang D, Swaika A, Foran J, Ghosh R, Tun H, Colon-Otero G, Kelly K, Chanan-Khan A, Ailawadhi S.

Clin Lymphoma Myeloma Leuk. 2015 Jun 19. pii: S2152-2650(15)00382-1. doi: 10.1016/j.clml.2015.06.005. [Epub ahead of print]


Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.

Chitta K, Paulus A, Akhtar S, Blake MK, Caulfield TR, Novak AJ, Ansell SM, Advani P, Ailawadhi S, Sher T, Linder S, Chanan-Khan A.

Br J Haematol. 2015 May;169(3):377-90. doi: 10.1111/bjh.13304. Epub 2015 Feb 17.


Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type.

Swaika A, Menke DM, Jain MK, Sher T.

Ann Hematol. 2015 May;94(5):895-6. doi: 10.1007/s00277-014-2253-3. Epub 2014 Nov 15. No abstract available.


Pathophysiology and treatment of cardiac amyloidosis.

Gertz MA, Dispenzieri A, Sher T.

Nat Rev Cardiol. 2015 Feb;12(2):91-102. doi: 10.1038/nrcardio.2014.165. Epub 2014 Oct 14.


First report of Nocardia beijingensis infection in an immunocompetent host in the United States.

Crozier JA, Andhavarapu S, Brumble LM, Sher T.

J Clin Microbiol. 2014 Jul;52(7):2730-2. doi: 10.1128/JCM.00588-14. Epub 2014 May 14.


Mantle cell lymphoma and diffuse large B-cell lymphoma of the testis: a unique case of composite non-Hodgkin lymphoma.

Andhavarapu S, Crozier JA, Jiang L, Sher T.

Eur J Haematol. 2014 Dec;93(6):537-42. doi: 10.1111/ejh.12344. Epub 2014 May 22.


Recent advances in the diagnosis and management of cardiac amyloidosis.

Sher T, Gertz MA.

Future Cardiol. 2014 Jan;10(1):131-46. doi: 10.2217/fca.13.85. Review.


Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells.

Chitta KS, Khan AN, Ersing N, Swaika A, Masood A, Paulus A, Qadeer A, Advani P, Sher T, Miller KC, Lee K, Chanan-Khan AA.

Leuk Lymphoma. 2014 Mar;55(3):652-61. doi: 10.3109/10428194.2013.807927. Epub 2013 Jul 1.


Multiple myeloma mimicking metastatic pancreas cancer.

Sher T, Bhat S, Jitawatanarat P, Desai N, Qiu J, Ma WW.

J Clin Oncol. 2013 Jun 20;31(18):e297-9. doi: 10.1200/JCO.2012.44.8845. Epub 2013 May 13. No abstract available.


Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ; Mayo Clinic.

Mayo Clin Proc. 2013 Apr;88(4):360-76. doi: 10.1016/j.mayocp.2013.01.019. Erratum in: Mayo Clin Proc. 2013 Jul;88(7):777. Stewart, Keith [corrected to Stewart, A Keith].


Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.

Sher T, Hayman SR, Gertz MA.

Clin Adv Hematol Oncol. 2012 Oct;10(10):644-51. Erratum in: Clin Adv Hematol Oncol. 2012 Nov;10(11):766.


Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1.

Chitta KS, Paulus A, Ailawadhi S, Foster BA, Moser MT, Starostik P, Masood A, Sher T, Miller KC, Iancu DM, Conroy J, Nowak NJ, Sait SN, Personett DA, Coleman M, Furman RR, Martin P, Ansell SM, Lee K, Chanan-Khan AA.

Leuk Lymphoma. 2013 Feb;54(2):387-96. doi: 10.3109/10428194.2012.713481. Epub 2012 Aug 27.


Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups.

Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T, Chanan-Khan A.

Br J Haematol. 2012 Jul;158(1):91-8. doi: 10.1111/j.1365-2141.2012.09124.x. Epub 2012 Apr 26.


Multiple myeloma and immunomodulation: regulating the regulatory cells.

Kasyapa CS, Sher T, Chanan-Khan AA.

Leuk Lymphoma. 2012 Jul;53(7):1253-4. doi: 10.3109/10428194.2012.670233. Epub 2012 Apr 3. No abstract available.


Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.

Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, Wood M, Masood A, Lee K, Chanan-Khan AA.

J Support Oncol. 2012 Jul-Aug;10(4):155-9. doi: 10.1016/j.suponc.2011.10.006. Epub 2012 Jan 4.


Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.

Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan A.

Br J Haematol. 2012 Apr;157(1):59-66. doi: 10.1111/j.1365-2141.2011.08984.x. Epub 2011 Dec 15.


Targeted treatment for chronic lymphocytic leukemia.

Masood A, Sher T, Paulus A, Miller KC, Chitta KS, Chanan-Khan A.

Onco Targets Ther. 2011;4:169-83. doi: 10.2147/OTT.S7173. Epub 2011 Nov 4.


Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.

Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP, Chanan-Khan A.

Leuk Lymphoma. 2012 Jun;53(6):1174-82. doi: 10.3109/10428194.2011.637212. Epub 2011 Dec 6.


Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, Swaika A, Wallace PK, Mashtare TL Jr, Wilding G, Lee K, Czuczman MS, Borrello I, Bangia N.

Br J Haematol. 2011 Nov;155(4):457-67. doi: 10.1111/j.1365-2141.2011.08882.x. Epub 2011 Oct 20.


A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.

Sher T, Ailawadhi S, Miller KC, Manfredi D, Wood M, Tan W, Wilding G, Czuczman MS, Hernandez-Ilizaliturri FJ, Hong F, Sood R, Soniwala S, Lawrence W, Jamshed S, Masood A, Iancu D, Lee K, Chanan-Khan A.

Br J Haematol. 2011 Jul;154(1):104-10. doi: 10.1111/j.1365-2141.2011.08703.x. Epub 2011 May 9.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk